Cardiol Therapeutics (CRDL) Cash & Equivalents (2020 - 2026)

Cardiol Therapeutics' Cash & Equivalents history runs 7 years deep, the most recent figure standing at $20.2 million for Q1 2026.

• Quarterly Cash & Equivalents rose 24.31% year-over-year to $20.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $20.2 million (up 24.31% YoY) and the FY2025 annual result came in at $15.4 million, down 29.84% from the prior year.
• Cash & Equivalents was $20.2 million for Q1 2026 at Cardiol Therapeutics, up from $15.4 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $59.1 million in Q1 2022 and bottomed at $8.4 million in Q3 2025.
• A 5-year average of $28.2 million and a median of $21.9 million in 2024 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2022 — Cash & Equivalents jumped 120.75% — and 2024, when it sank 61.49%.
• Cardiol Therapeutics' Cash & Equivalents stood at $43.8 million in 2022, then plunged by 41.43% to $25.7 million in 2023, then decreased by 14.68% to $21.9 million in 2024, then slipped by 29.84% to $15.4 million in 2025, then jumped by 31.4% to $20.2 million in 2026.
• Business Quant data shows CRDL's Cash & Equivalents at $20.2 million in Q1 2026, $15.4 million in Q4 2025, and $8.4 million in Q3 2025.